SG11201806122YA - Proteinaceous compounds and uses therefor - Google Patents

Proteinaceous compounds and uses therefor

Info

Publication number
SG11201806122YA
SG11201806122YA SG11201806122YA SG11201806122YA SG11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA
Authority
SG
Singapore
Prior art keywords
international
pct
pkc
english
february
Prior art date
Application number
SG11201806122YA
Other languages
English (en)
Inventor
Sudha Rao
Peter Milburn
Original Assignee
Univ Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900314A external-priority patent/AU2016900314A0/en
Application filed by Univ Canberra filed Critical Univ Canberra
Publication of SG11201806122YA publication Critical patent/SG11201806122YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201806122YA 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor SG11201806122YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016900314A AU2016900314A0 (en) 2016-02-01 Proteinaceous compounds and uses therefor
PCT/AU2017/050083 WO2017132728A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Publications (1)

Publication Number Publication Date
SG11201806122YA true SG11201806122YA (en) 2018-08-30

Family

ID=59499146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806122YA SG11201806122YA (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Country Status (8)

Country Link
US (1) US10487115B2 (hr)
EP (1) EP3411061A4 (hr)
JP (2) JP7341451B2 (hr)
CN (2) CN108883155A (hr)
AU (1) AU2017214761B2 (hr)
CA (1) CA3011870A1 (hr)
SG (1) SG11201806122YA (hr)
WO (1) WO2017132728A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587120A (zh) * 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ES2231819T3 (es) 1995-06-07 2005-05-16 Inex Pharmaceuticals Corp Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO2000036083A2 (en) 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
CA2405728A1 (en) 2000-07-31 2002-02-07 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
CA2489458A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
JP2006521791A (ja) * 2003-02-28 2006-09-28 ノバルティス アクチエンゲゼルシャフト プロテインキナーゼＣθの触媒ドメインの立体構造、その方法および使用
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
WO2007097561A1 (en) 2006-02-20 2007-08-30 Ewha University - Industry Collaboration Foundation Peptide having cell membrane penetrating activity
CN103328499A (zh) * 2010-11-01 2013-09-25 悉尼科技大学 免疫调节剂及其用途
EP2683419B1 (en) * 2011-03-11 2018-05-09 Vib Vzw Molecules and methods for inhibition and detection of proteins
CN112225819A (zh) 2012-09-27 2021-01-15 不列颠哥伦比亚大学 肽导向的蛋白敲低
SG11201601408PA (en) 2013-09-18 2016-04-28 Univ Canberra Stem cell modulation ii
CA2958704A1 (en) * 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor

Also Published As

Publication number Publication date
CA3011870A1 (en) 2017-08-10
JP2022023949A (ja) 2022-02-08
CN116082457A (zh) 2023-05-09
US20190040103A1 (en) 2019-02-07
CN108883155A (zh) 2018-11-23
JP7341451B2 (ja) 2023-09-11
WO2017132728A1 (en) 2017-08-10
US10487115B2 (en) 2019-11-26
AU2017214761B2 (en) 2024-02-01
AU2017214761A1 (en) 2018-08-02
JP2019506167A (ja) 2019-03-07
EP3411061A4 (en) 2019-07-10
EP3411061A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201804915RA (en) Methods for treating huntington's disease
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201901624RA (en) Lysine specific histone demethylase-1 inhibitors and uses therefor
SG11201909011PA (en) Niraparib compositions
SG11201900743UA (en) Multiple function exercise device
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201909837YA (en) Methods for treating lung disorders
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201810975UA (en) Method for stabilizing proteins
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805191SA (en) Yeast cell
SG11201803762RA (en) High viscosity base stock compositions
SG11201909872WA (en) Stability of short path evaporation treated oils
SG11201406927VA (en) Electrolytic cell equipped with concentric electrode pairs